Why is HUTCHMED stock surging today?

HUTCHMED stock experienced a significant surge of nearly 5.0% to trade at HK$20.14 following the disclosure of positive Phase III study results. The trial evaluated the combination of savolitinib (Orpathys) and osimertinib (Tagrisso) in EGFR-mutant non-small cell lung cancer patients who had previously progressed on osimertinib and showed high MET overexpression or amplification.

The study met its co-primary endpoints, demonstrating statistically and clinically meaningful improvements in both progression-free survival and overall survival. This dual-endpoint success is rare and highly significant in oncology development. The positive results come at a time when the stock has faced recent headwinds, with Goldman Sachs reducing its price target and Bank of Communications International cutting its target.

The data effectively resets the near-term narrative for HUTCHMED, reinforcing the commercial and clinical value of its MET-inhibitor franchise and its collaboration with AstraZeneca. The broader Hong Kong market also provided support, with the Hang Seng Index rising by 0.7% and the Hang Seng Tech Index climbing around 1.1%. While the macro environment was favorable, HUTCHMED's strong performance was primarily driven by its own company-specific catalyst.

The stock reached an intraday high of HK$20.90, surpassing the broader market's modest advance. With the stock trading well below its 52-week high of HK$28.80, there remains significant potential for re-rating if the SAFFRON data holds up to regulatory and peer scrutiny.